222 related articles for article (PubMed ID: 34655573)
1. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.
Salas JH; Urbanowicz RA; Guest JD; Frumento N; Figueroa A; Clark KE; Keck Z; Cowton VM; Cole SJ; Patel AH; Fuerst TR; Drummer HE; Major M; Tarr AW; Ball JK; Law M; Pierce BG; Foung SKH; Bailey JR
Gastroenterology; 2022 Feb; 162(2):562-574. PubMed ID: 34655573
[TBL] [Abstract][Full Text] [Related]
2. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
[TBL] [Abstract][Full Text] [Related]
3. A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns.
Chumbe A; Grobben M; Capella-Pujol J; Koekkoek SM; Zon I; Slamanig S; Merat SJ; Beaumont T; Sliepen K; Schinkel J; van Gils MJ
Virus Res; 2024 Mar; 341():199308. PubMed ID: 38171391
[TBL] [Abstract][Full Text] [Related]
4. Defining Breadth of Hepatitis C Virus Neutralization.
Kinchen VJ; Bailey JR
Front Immunol; 2018; 9():1703. PubMed ID: 30116237
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
Wasilewski LN; Ray SC; Bailey JR
J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
[TBL] [Abstract][Full Text] [Related]
7. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.
Bailey JR; Wasilewski LN; Snider AE; El-Diwany R; Osburn WO; Keck Z; Foung SK; Ray SC
J Clin Invest; 2015 Jan; 125(1):437-47. PubMed ID: 25500884
[TBL] [Abstract][Full Text] [Related]
8. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
[TBL] [Abstract][Full Text] [Related]
9. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
10. Optimization of the pseudoparticle system for standardized assessments of neutralizing antibodies against hepatitis C virus.
Chumbe A; Urbanowicz RA; Sliepen K; Koekkoek SM; Molenkamp R; Tarr AW; Ball JK; Schinkel J; van Gils MJ
J Gen Virol; 2022 Nov; 103(11):. PubMed ID: 36399377
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
Tarr AW; Urbanowicz RA; Hamed MR; Albecka A; McClure CP; Brown RJ; Irving WL; Dubuisson J; Ball JK
J Virol; 2011 May; 85(9):4246-57. PubMed ID: 21325403
[TBL] [Abstract][Full Text] [Related]
12. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
13. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
14. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.
Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M
Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725
[TBL] [Abstract][Full Text] [Related]
15. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
[TBL] [Abstract][Full Text] [Related]
16. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
[TBL] [Abstract][Full Text] [Related]
17. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
[TBL] [Abstract][Full Text] [Related]
18. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
Front Immunol; 2019; 10():1145. PubMed ID: 31178869
[TBL] [Abstract][Full Text] [Related]
19. Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency.
Frumento N; Figueroa A; Wang T; Zahid MN; Wang S; Massaccesi G; Stavrakis G; Crowe JE; Flyak AI; Ji H; Ray SC; Shaw GM; Cox AL; Bailey JR
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35588376
[TBL] [Abstract][Full Text] [Related]
20. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
